噬菌体裂解酶应用研究进展

近年来,随着抗生素的滥用,导致多重耐药性菌株出现的频率加快。因细菌感染导致死亡的人数逐年增多,人类健康面临巨大挑战,因此研制新型抗菌药物刻不容缓。噬菌体裂解酶因其高效的杀菌能力及高度的宿主专一性而成为新一代抗菌制剂的候选之一。其是一种细胞壁水解酶,在双链DNA噬菌体复制后期被合成,通过水解细胞壁肽聚糖上的化学键,从而裂解细菌细胞壁,释放出子代噬菌体。本文系统地介绍了噬菌体裂解酶的研究进展,为相关裂解酶抗菌药物的研发做出有益探索。     

细菌细胞壁构造的教学

细菌的细胞壁位于细菌细胞的表面,是一层较为坚韧、略带弹性的结构,它除具有保护细胞、维持细胞外形和对大分子的运输具有选择性等作用外,还为细菌鞭毛提供可靠的支点,并和细菌的抗原性、致病性、对噬菌体的敏感性以及与几种重要抗生素的抑菌机制密切有关。因此细菌细胞壁的教学在微生物学教学中占有重要的地位。1应用比较的方法讲解肽聚糖的结构肽聚糖（peptidoglycan）肽聚糖是细菌等原核生物所特有的成分,占细胞壁物质总量的40～90％。它由聚糖链、短肽和肽桥三部分组成[1]。通过比较金黄色葡萄球菌（Staphylococcusaureus）和大肠…     

噬菌体裂解酶——现状与未来

噬菌体裂解酶是一种由DNA噬菌体基因编码的高特异性酶, 可高效消化细菌细胞壁。革兰氏阳性菌噬菌体裂解酶的结构域相似, 裂解效率高, 与抗生素具协同抗菌作用, 且不易产生耐受性菌株, 抗体等体液因子对裂解酶的裂解活性影响小, 裂解酶作为一种潜在抗感染药物具有重要的研究价值。目前已建立了多种病原菌裂解酶应用的动物模型, 在防控耐药性病原菌感染上取得重要进展。本文就噬菌体裂解酶的抗菌作用进行综述。     

噬菌体裂解酶的抗菌特性

摘要：噬菌体裂解酶是一类细胞壁水解酶,可水解肽聚糖,造成细菌的破裂。裂解酶一般具有两到三个结构域,参与对底物的催化和结合。作为一种新型的杀菌制剂,裂解酶已被越来越多地应用于化脓链球菌、肺炎链球菌、金黄色葡萄球菌等革兰氏阳性细菌病的治疗。与抗生素治疗相比,裂解酶不易使细菌产生抗性且作用相对专一,这可能是解决现在日趋严重的细菌耐药性的一种可行方法。另外,裂解酶还具有高效性,作用协同性,且自身抗体不削弱其作用等优势,使之成为未来预防、控制致病菌一种可能的新途径。     

溶葡球菌酶高效表达与应用

溶葡球菌酶(lysostaphin,Lys)是采用基因克隆技术使溶葡球菌酶基因实现外源表达所产生的蛋白质。它是Zn2+依赖的金属蛋白酶,具有肽链内切酶活性,能专一性地水解葡萄球菌细胞壁Gly五肽桥联,使金黄色葡萄球菌(特别是MRSA)细胞壁破裂,达到溶菌杀菌作用,而不产生耐药性。作为一种抗菌剂,在兽药与临床等领域具有巨大的应用潜力。综述对溶葡球菌酶的来源、作用机制、不同表达系统及前景与展望进行综述。     

噬菌体内溶素的酶学特性及其应用前景

噬菌体内溶素是噬菌体在入侵宿主菌及侵染后期释放过程中合成的一类酶蛋白,该蛋白质能够破坏宿主细胞壁肽聚糖层。噬菌体编码的内溶素有四种类型:葡糖苷酶、酰胺酶、肽链内切酶和转糖基酶。大部分噬菌体内溶素由于缺少信号肽无法分泌表达,通常需要另外一种噬菌体编码的穴蛋白(holin)破坏细胞膜,然后才能够进入到细胞周间质裂解细菌细胞壁。大部分噬菌体内溶素可以特异地作用于自身宿主菌,同时也可以利用基因工程手段有目的地改造成功能特异的酶蛋白,因此可以用来作为生物制剂预防及控制微生物感染。     

提高噬菌体裂解酶抗菌活性的研究进展

随着细菌耐药性问题的日益严重,人们开始寻求新型抗菌制剂。噬菌体裂解酶是一种由ds DNA噬菌体编码的水解酶,能高效特异性地裂解细菌细胞壁且不易使细菌产生耐药性。由于天然裂解酶具有宿主谱窄,不能裂解革兰阴性菌等缺点,研究者对裂解酶进行了大量的设计改造。本研究主要对提高噬菌体裂解酶抗菌活性的研究进展进行综述。     

结核杆菌 D29 噬菌体几丁质酶基因的表达及功能研究

噬菌体一般通过表达内溶素来降解宿主菌细胞壁上的肽聚糖 . 用 PCR 技术从结核杆菌 D29 噬菌体基因组中克隆了 gene10 ,并使其在大肠杆菌中得到了高效表达,蛋白质 C 端带有 6×His. 用镍柱亲和纯化了大肠杆菌表达的 gp10 蛋白可溶性部分 . 活性测定表明, gp10 不但具有几丁质酶活性,还具有溶菌酶活性,是一种双功能的酶 . 耻垢杆菌经 gp10 作用后,其生长受到抑制,扫描电镜观察发现部分耻垢杆菌被降解 . 说明与其他种类噬菌体降解细胞壁的方式不同, D29 噬菌体可能利用 gp10 的溶菌酶活性使结核杆菌细胞壁降解 . 这有助于揭示结核杆菌噬菌体与其宿主的相互作用机制,是关于噬菌体几丁质酶的首次报道 .     

肽聚糖的生物合成及其调控机制研究进展

肽聚糖(peptidoglycan)是细菌细胞壁的重要组成部分,对于维持细胞形态、大小及存活至关重要;同时,肽聚糖是众多常用抗生素的作用靶点。在细菌的正常生长过程中,肽聚糖不断地合成和水解,为了保证细胞壁的完整性,肽聚糖生物合成过程必然受到严谨的时空调控。肽聚糖的生物合成及其调控机制是微生物学中重要的基础研究之一,近年来国内外研究团队在该领域取得了突破性研究进展。基于此,本文综述了肽聚糖的从头合成和循环再利用过程,并重点阐述了肽聚糖合成关键酶——肽聚糖合酶及其调控机制的最新研究进展。最后,本文对未来需要加强研究的方向进行了展望。     

双歧杆菌及其表面分子对小鼠肠内致癌相关性细菌酶活性的影响

本文研究了分叉双歧杆菌及其脂磷壁酸、细胞壁肽聚糖对小鼠粪便中肠内细菌酶－β－葡萄糖醛酸酶、偶氮还原酶和硝酸盐还原酶活性的影响。结果表明,小鼠摄入双歧杆菌活菌、死菌、脂磷壁酸、细胞壁肽聚糖３周期间,肠内细菌偶氮还原酶、β－葡萄糖醛酸酶、硝酸盐还原酶活性降低,以活菌、死菌作用更为显著,二者无显著差异。     

Recombinant bacteriophage lysins as antibacterials

With the increasing worldwide prevalence of antibiotic resistant bacteria, bacteriophage endolysins (lysins) represent a very promising novel alternative class of antibacterial in the fight against infectious disease. Lysins are phage-encoded peptidoglycan hydrolases which, when applied exogenously (as purified recombinant proteins) to Gram-positive bacteria, bring about rapid lysis and death of the bacterial cell. A number of studies have recently demonstrated the strong potential of these enzymes in human and veterinary medicine to control and treat pathogens on mucosal surfaces and in systemic infections. They also have potential in diagnostics and detection, bio-defence, elimination of food pathogens and control of phytopathogens. This review discusses the extensive research on recombinant bacteriophage lysins in the context of antibacterials, and looks forward to future development and potential.     

链球菌噬菌体裂解酶在大肠杆菌中的表达、纯化及活性检测

噬菌体裂解酶是噬菌体产生的细胞壁水解酶,通过水解宿主菌细胞壁使子代噬菌体释放,在体外能高效且特异性地杀死细菌。本研究旨在克隆和表达链球菌噬菌体裂解酶PlyC,并测定其生物学活性。利用PCR方法扩增PlyC的2条肽链PlyCA和PlyCB,构建表达载体pET-32a(+)-PlyCA和pET-32a(+)-PlyCB,分别转化至大肠杆菌BL21(DE3)中,以0.7 mmol/L IPTG在30 oC诱导7 h实现了高效表达,SDS-PAGE分析表明PlyCA和PlyCB表达量均可达菌体总蛋白的30%以上。采用Ni2+-NTA亲和层析法纯化目的蛋白,其纯度大于95%。用透析复性方法得到目的产物重组链球菌噬菌体裂解酶PlyC,以浊度法和平板计数法检测其体外抗菌效果,扫描电子显微镜观察裂解酶作用前后细菌细胞形态变化。结果表明重组PlyC能特异性裂解化脓性链球菌(A组β-溶血性链球菌),以4μg/mL浓度作用于OD600为0.56的菌液60 min后杀菌率达99.6%,扫描电镜观察结果显示该酶作用于菌体后,链球菌细胞裂解,呈碎片状态。本研究为开发一种新型、高效的链球菌感染疾病治疗药物打下了基础。     

裂解酶治疗的研究进展与应用前景

多耐药病原细菌的不断出现和传播给公共医疗造成了严峻的威胁和挑战,开发新的抗菌分子迫在眉睫。噬菌体裂解酶来源于噬菌体,具有独特的进化和选择优势,不仅能高效快速的杀灭多耐药细菌,而且不易诱导细菌产生新的耐药性。本文对噬菌体裂解酶的结构和功能进行了简要的介绍,重点综述了裂解酶在抗细菌感染中近年的研究进展和应用前景。     

Bacteriophage lysins as effective antibacterials

Lysins are highly evolved enzymes produced by bacteriophage (phage for short) to digest the bacterial cell wall for phage progeny release. In Gram-positive bacteria, small quantities of purified recombinant lysin added externally results in immediate lysis causing log-fold death of the target bacterium. Lysins have been used successfully in a variety of animal models to control pathogenic antibiotic resistant bacteria found on mucosal surfaces and infected tissues. The advantages over antibiotics are their specificity for the pathogen without disturbing the normal flora, the low chance of bacterial resistance to lysins, and their ability to kill colonizing pathogens on mucosal surfaces, a capacity previously unavailable. Thus, lysins may be a much needed anti-infective in an age of mounting antibiotic resistance.     

Bacteriophage lytic enzymes: novel anti-infectives

Bacteriophage lytic enzymes, or lysins, are highly evolved molecules produced by bacterial viruses (bacteriophage) to digest the bacterial cell wall for bacteriophage progeny release. Small quantities of purified recombinant lysin added to gram-positive bacteria causes immediate lysis resulting in log-fold death of the target bacterium. Lysins have now been used successfully in animal models to control pathogenic antibiotic resistant bacteria found on mucosal surfaces and in blood. The advantages over antibiotics are their specificity for the pathogen without disturbing the normal flora, the low chance of bacterial resistance to lysins and their ability to kill colonizing pathogens on mucosal surfaces, capabilities that were previously unavailable. Thus, lysins could be an effective anti-infective in an age of mounting antibiotic resistance.     

Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins

The recombinant lysins of lytic phages, when applied externally to Gram-positive bacteria, can be efficient bactericidal agents, typically retaining high specificity. Their development as novel antibacterial agents offers many potential advantages over conventional antibiotics. Protein engineering could exploit this potential further by generating novel lysins fit for distinct target populations and environments. However, access to the peptidoglycan layer is controlled by a variety of secondary cell wall polymers, chemical modifications, and (in some cases) S-layers and capsules. Classical lysins require a cell wall-binding domain (CBD) that targets the catalytic domain to the peptidoglycan layer via binding to a secondary cell wall polymer component. The cell walls of Gram-positive bacteria generally have a negative charge, and we noticed a correlation between (positive) charge on the catalytic domain and bacteriolytic activity in the absence of the CBD (nonclassical behavior). We investigated a physical basis for this correlation by comparing the structures and activities of pairs of lysins where the lytic activity of one of each pair was CBD-independent. We found that by engineering a reversal of sign of the net charge of the catalytic domain, we could either eliminate or create CBD dependence. We also provide evidence that the S-layer of Bacillus anthracis acts as a molecular sieve that is chiefly size-dependent, favoring catalytic domains over full-length lysins. Our work suggests a number of facile approaches for fine-tuning lysin activity, either to enhance or reduce specificity/host range and/or bactericidal potential, as required.     

噬菌体裂解酶研究进展

噬菌体裂解酶是双链DNA噬菌体所特有的细胞壁水解酶。研究表明,所有噬菌体裂解酶在结构上具有相似性,即含有2个结构域：比较保守的N端催化区和差异较大的C端特异性结合区。裂解酶的高亲和性与种属特异的细胞壁糖基有关,而后常常是细菌存活的必要成分。所以,细菌难以产生对裂解酶的抗性。本简要综述噬茵体裂解酶的研究进展。     

Bacteriophage and their lysins for elimination of infectious bacteria

When phages were originally identified, the possibility of using them as antibacterial agents against pathogens was immediately recognized and put into practise based on the knowledge available at the time. However, with the advent of antibiotics a decline in the use of phage as therapeutics followed. Phages did, however, become more useful in the study of fundamental aspects of molecular biology and in the diagnostic laboratory for the identification of pathogenic bacteria. More recently, the original application of phage as therapeutics to treat human and animal infections has been rekindled, particularly in an era where antibiotic resistance has become so problematic/commonplace. Phage lysins have also been studied and utilized in their own right as potential therapeutics for the treatment of bacterial infections. Indeed the past decade has seen a considerable amount of research worldwide focused on the engineering of phages as antibacterial agents in a wide range of applications. Furthermore, the US Food and Drug Administration and/or the US Department of Agriculture have recently approved commercial phage preparations to prevent bacterial contamination of livestock, food crops, meat and other foods. Such developments have prompted this review into the status of phage research as it pertains to the control of infectious bacteria.